Inlyta is not usually bad for the kidneys, in fact, research has found no difference with regards to kidney toxicity between patients with advanced renal cell carcinoma (RCC) and healthy volunteers regardless of baseline kidney function and recommend no adjustment to the starting dose of Inlyta for patients with pre-existing mild-to-severe renal impairment (kidney disease).
When Inlyta is used in combination with either avelumab or pembrolizumab, acute kidney injury (a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days) was reported in only 1.4% to 2.3% of patients respectively, and is considered an uncommon/rare side effect.
Inlyta in combination with avelumab or pembrolizumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).